Plus: glucose levels and cognitive decline; fractures in African American & Hispanic patients
July 28, 2020 : DCMS #512 |
|
Letter from the Editor
Since February we have been looking for care solutions for our patients that have been diagnosed with the coronavirus. At first we thought it was strictly a respiratory problem and all damage was to the lungs. As time has progressed, we have seen the effect COVID-19 has had on the circulatory system, and there especially seems to be a problem with younger patients and blood clots. The desire to help prevent serious effects is leading many companies to get accelerated approval for currently used medications.
This week our intern Zahra Hashemy, PharmD. Candidate, USF Taneja College of Pharmacy, tracks the accelerated approval of a diabetes drug for reduction of death and heart failure after a heart attack.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
TOP STORIES - Diabetes News and Research |
|
| Preventing Heart Failure With Farxiga
The FDA has given a Fast Track Designation to accelerate study of Farxiga’s effect on reduction in mortality and heart failure after a heart attack. |
| |
|
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
